Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02509117 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT02509117: Completed Phase 1 study, sponsored by Pfizer.
NCT02509117 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 55 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02509117, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
Primary Outcome
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug up to the follow
Interventions
- DRUG Placebo single dose
- DRUG PF-06751979 single ascending dose
- DRUG PF-06751979 multiple ascending dose
- DRUG Placebo multiple dose
- DRUG PF-06751979 multiple dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
What the finished NCT02509117 record still lists
NCT02509117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Placebo single dose is the first listed.
NCT02509117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02509117 about?
NCT02509117 is a clinical study titled "First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979". The purpose of this study is to evaluate the safety, tolerability, PK and PD of PF-06751979 following oral doses in healthy adult and healthy elderly subjects.
What is the current status of trial NCT02509117?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2015-07. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02509117?
The interventions under investigation include: Placebo single dose (DRUG), PF-06751979 single ascending dose (DRUG), PF-06751979 multiple ascending dose (DRUG), Placebo multiple dose (DRUG), PF-06751979 multiple dose (DRUG).
Who is sponsoring clinical trial NCT02509117?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02509117's enrollment target sits among peer trials
55 918th of 2000 higher than 1,070 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia